All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub
Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Legend Biotech, Pfizer, Roche, and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
View on  

Important announcement

🚨NEWS🚨

@US_FDA
clears an investigational new drug application for KLN-1010, a gene therapy designed to generate anti-BCMA CAR-T cells in vivo, for the treatment of R/R #MultipleMyeloma, enabling expansion of the ongoing phase I inMMyCAR trial.

Read more: https://loom.ly/IFxc874
View all drug updates

More drug updates

VIEW ALL

Important announcement

🚨NEWS🚨 Indication extension application submitted to @EMA_News for teclistamab + SC daratumumab for the treatment of RRMM with ≥1 prior LOT; based on data from the phase III MajesTEC-3 trial. Read more: https://loom.ly/DYkQBGc

Jan 7, 2026

Important announcement

@US_FDA grants Commissioner’s National Priority Voucher (CNPV) to teclistamab in combination with daratumumab for the treatment of relapsed/refractory #MultipleMyeloma, based on data from the phase III MajesTEC-3 trial. Read more: https://loom.ly/fzkSZV8

Dec 17, 2025

Important announcement

@newsgovhk approves supplemental new drug application for selinexor, an XPO1 inhibitor, in combination with bortezomib + dexamethasone (XVd) for adult patients with #MultipleMyeloma after ≥1 prior therapy in Hong Kong. Read more: https://loom.ly/Y5kNsdc

Dec 4, 2025

Important announcement

Nov 28, 2025